HeartBeam to Attend Investor and Industry Conferences in March, Focused on Providing Updates on Commercial Launch and Unveiling 12-Lead ECG Extended Wear Patch

Download as PDF

SANTA CLARA--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that management will attend key investor and industry conferences in March 2026.

HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, 2026. Management will host a presentation webcast on March 16 at 11:20 a.m. Eastern time (8:20 a.m. Pacific time) and host one-on-one meetings with institutional and retail investors.

Mr. Eno and Mr. Cruickshank will also attend the 38th Annual ROTH Conference taking place in Dana Point, California in person on March 23-24, 2026. Mr. Eno will participate on the panel ‘Technologies Advancing Healthy Aging’ on March 23 at 5:00 p.m. Eastern time (2:00 p.m. Pacific time). They will also host one-on-one meetings with institutional and retail investors.

Mr. Eno, Founder and President Dr. Branislav Vajdic and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology’s annual scientific conference on March 28-30, 2026. The HeartBeam team will have a booth (#209) and will provide demos of their recently FDA-cleared HeartBeam System. In addition, the team will provide demos of the working prototype 12-lead ECG extended wear patch (not FDA-approved) to physicians and potential industry partners.

Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Date: Monday, March 16 and Tuesday, March 17, 2026
Location: Virtual
Format: Virtual 1x1 Meetings and Presentation
Attendees: Chief Executive Officer Robert Eno, Chief Financial Officer Timothy Cruickshank
Presentation: March 16 at 11:20 a.m. Eastern time (8:20 a.m. Pacific time)
Webcast: https://event.summitcast.com/view/2MZVg3DCx8a3zxe3mMMekq/7Ks3NGaATv8kxYQL7zN9Rk
Conference Website: Click here

38th Annual ROTH Conference
Date: Monday, March 23 and Tuesday, March 24, 2026
Location: Dana Point, CA
Format: In-person 1x1 Meetings and Panel Discussion
Attendees: Chief Executive Officer Robert Eno, Chief Financial Officer Timothy Cruickshank
Panel: ‘Technologies Advancing Healthy Aging’ March 23 at 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
Track: Consumer
Room: BLUE – CONSUMER - SALON 2
Conference Website: Click here

ACC.26 American College of Cardiology’s Annual Scientific Session & Expo
Date: Saturday, March 28 - Monday, March 30
Location: New Orleans, LA
Format: In-person demos of FDA-cleared HeartBeam System and working prototype of 12-lead ECG extended wear patch monitor
Attendees: Chief Executive Officer Robert Eno, Founder and President Dr. Branislav Vajdic, Chief Commercial Officer Bryan Humbarger
HeartBeam Booth #209
Conference Website: Click here

For more information on the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, the 38th Annual ROTH Conference, ACC.26 or to schedule a one-on-one meeting with HeartBeam management, please contact your conference representative or you may email your request to BEAT@mzgroup.us or call Chris Tyson at (949) 491-8235.

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.

1Cleared Indications for Use

The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.

Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us

Media Contact:
media@heartbeam.com

Source: HeartBeam, Inc.

Released March 9, 2026